However, EGFR expression level and gene copy number are not predictive for response to treatment with EGFR‐targeted therapies plus platinum/5‐fluorouracil as first‐line therapy for patients with R/M HNSCC (Licitra et al., 2011, 2013). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.